Anti-TFAM antibodies are detected in about one third of patients with systemic lupus erythematosus and are associated with a threefold higher risk for thrombotic events.
Long-term control of cardiovascular risk factors and sustained clinical remission help to mitigate the higher risk for atherosclerosis progression in patients with lupus.